Jon Jones
Has participated in:
-
Zur klinischen Relevanz des prostataspezifischen Antigens (PSA)
-
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
-
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
-
The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo